Relief Therapeutics Holding AG (RLFTF)

[trademax42]

Its more than a story. Independent research paper supports what the drug can do. Someone from the Johns Hopkins School of Medicine is on the paper, August 4, 2020. imo

"Vasoactive Intestinal Peptide (VIP) is known to bind to and protect the Alveolar Type II cell by blocking replication of the SARS-CoV-2 virus, upregulating surfactant production, blocking apoptosis, and blocking cytokine effects. RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP) has been granted Fast Track Designation and is currently in phase 2/3 placebo-controlled trials."

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228

So far this “looks” like a great story.

$RLFTF

Just my opinion of course.